Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1116575 10.3389/fphar.2022.1116575 Pharmacology Correction Corrigendum: Improving therapy of pharmacoresistant epilepsies: The role of fenfluramine Dini et al. 10.3389/fphar.2022.1116575 Dini Gianluca 1 * Tulli Eleonora 1 Dell’Isola Giovanni Battista 1 Mencaroni Elisabetta 1 Di Cara Giuseppe 1 Striano Pasquale 2 3 Verrotti Alberto 1 1 Department of Pediatrics, University of Perugia, Perugia, Italy 2 Pediatric Neurology and Muscular Diseases Unit, IRCCS “G. Gaslini” Institute, Genoa, Italy 3 Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy

Edited and reviewed by: Annalisa Capuano, University of Campania Luigi Vanvitelli, Italy

 *Correspondence: Gianluca Dini, gianlucadini90@gmail.com

This article was submitted to Obstetric and Pediatric Pharmacology, a section of the journal Frontiers in Pharmacology

 05 01 2023 2022 13 1116575 05 12 2022 21 12 2022 Copyright © 2023 Dini, Tulli, Dell’Isola, Mencaroni, Di Cara, Striano and Verrotti. 2023 Dini, Tulli, Dell’Isola, Mencaroni, Di Cara, Striano and Verrotti

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Improving therapy of pharmacoresistant epilepsies: The role of fenfluramine by Dini G, Tulli E, Dell’Isola GB, Mencaroni E, Di Cara G, Striano P and Verrotti A (2022). Front. Pharmacol. 13:832929. doi: 10.3389/fphar.2022.832929 fenfluramine pharmacoresistant epilepsy Dravet syndrome Lennox-Gastaut syndrome anti-seizure medication (ASM)

In the published article, there was an error. The conclusions of the article should be more cautionary and provide a more objective stance on the benefits and risks of this drug and its use. As such, a correction has been made to the Conclusion, final sentence. The original sentence reads as follows: “FFA showed an overall favorable profile of safety and tolerability, with mostly mild side effects, pointing out that significant benefits outweigh potential cardiac risks.”

The corrected sentence appears below: “FFA showed an overall favorable profile of safety and tolerability, with mostly mild side effects, suggesting that benefits might outweigh potential cardiac risks, although this will need to be established in targeted investigations.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.